| Detected | Trial | Change |
|---|---|---|
| 2026-08-09 | NCT06010667 A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or… |
overall status: Not Yet Recruiting → Unknown |
| 2026-08-04 | NCT06210971 Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in… |
Enrollment closed, study ongoing |
| 2026-08-04 | NCT06210971 Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in… |
date change Primary completion moved earlier: 2026-02-01 -> 2025-09-30 |
| 2026-08-04 | NCT06949111 Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon… |
date change Primary completion pushed: 2027-02 -> 2028-05-30 |
| 2026-08-04 | NCT06949111 Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon… |
date change Completion pushed: 2029-03 -> 2030-03 |
| 2026-08-04 | NCT07179900 Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic… |
Recruitment opened |
| 2026-08-01 | NCT07057089 Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced… |
critical Recruitment suspended |
| 2026-08-01 | NCT07057089 Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced… |
critical Recruitment suspended: Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug supply. |
| 2026-08-01 | NCT07448077 Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC |
Recruitment opened |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-04 | NCT07744932 SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma | Phase 2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment… | HER2-positive Breast Cancer | Recruiting |
| NCT05525767 | Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer | Solid Tumor | Recruiting |
| NCT07004335 | Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With… | PD-(L)1 | Not Yet Recruiting |
| NCT07668570 | SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma | HCC - Hepatocellular Carcinoma | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT04290793 | Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by… | Breast Cancer | Active, Not Recruiting |
| NCT07585279 | A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal… | Metastatic Colorectal Cancer (CRC) | Not Yet Recruiting |
| Phase 2 | |||
| NCT03964753 | Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal… | Esophageal Squamous Cell Carcinoma | Recruiting |
| NCT05241028 | Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | Recruiting |
| NCT06371482 | Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer… | SCLC, Limited Stage | Recruiting |
| NCT06184698 | Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic… | Colorectal Cancer | Recruiting |
| NCT06646588 | Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal… | Esophageal Neoplasms | Recruiting |
| NCT04138719 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant… | Breast Cancer | Recruiting |
| NCT04159142 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment… | Triple Negative Breast Cancer | Recruiting |
| NCT07266480 | Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell… | Squamous Oesophageal Cancer | Recruiting |
| NCT06107673 | Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant… | Breast Cancer | Recruiting |
| NCT07289997 | Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the… | AFP Gastric or Gastroesophageal Junction Adenocarcinoma | Recruiting |
| NCT07290010 | The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With… | Esophageal Squamous Cell Carcinoma (ESCC) | Recruiting |
| NCT07492394 | Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | Breast Cancer | Recruiting |
| NCT07635342 | Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | HER2-positive Breast Cancer | Recruiting |
| NCT06435260 | Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for… | Pancreatic Cancer | Recruiting |
| NCT07448077 | Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC | Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer | Recruiting |
| NCT06949098 | Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low… | Rectal Cancer Stage I | Recruiting |
| NCT06949111 | Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon… | Colon Cancer | Recruiting |
| NCT07179900 | Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic… | Hepatocellular Carcinoma | Recruiting |
| NCT07744932 | SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma | Oligometastatic Clear Cell Renal Cell Carcinoma | Recruiting |